Loading
Allopurinol / Heart Failure Preserved Ejection Fraction / Resistant Hypertension · Phase 2 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed Phase 2 trial registration for allopurinol in African American Veterans with resistant hypertension and heart failure with preserved ejection fraction. No results are posted in this registry record, so efficacy, safety, or clinical benefit cannot be assessed. The trial measured diastolic function, exercise capacity, and quality of life over 8 weeks.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Heart Failure Preserved Ejection Fraction, Resistant Hypertension; age from 18 Years; to 75 Years. Intervention: Allopurinol - African American Veterans. n = 40. 1 site: United States.
This is a completed Phase 2 trial registration for allopurinol in African American Veterans with resistant hypertension and heart failure with preserved ejection fraction. No results are posted in this registry record, so efficacy, safety, or clinical benefit cannot be assessed. The trial measured diastolic function, exercise capacity, and quality of life over 8 weeks.
This is a registry record only; no efficacy or safety results are reported.
The source did not state who this applies to in practice.
Phase 2 interventional study with recruitment completed but no results reported in this registry record; cannot assess efficacy or safety until outcome data are published.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05888233). This is a study registration, not published results. Lead sponsor: VA Office of Research and Development. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 40 participants (ACTUAL). Conditions: Heart Failure Preserved Ejection Fraction, Resistant Hypertension. Interventions: DRUG: Allopurinol. Primary outcome measures: Normalized peak early diastolic filling rate (E) , 8 weeks; Six minute walk test , 8 weeks; Self Reported health survey for Heart Failure , 8 weeks; Self reported Health Survey , 8 weeks; Left ventricular end-diastolic volume index , 8 weeks; Left ventricular (LV) end-diastolic mass index , 8 weeks; Left ventricular (LV) end-diastolic fractional shortening , 8 weeks; Left ventricular (LV) end-diastolic mid-wall radius to wall thickness ratio , 8 weeks; Normalized peak late diastolic filling rate (A), EDV/s , 8 weeks. Brief summary: African American adults in the United States have the highest prevalence rate of high blood pressure (hypertension) and heart failure in the world. African Americans with treatment resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to Caucasians. This trial will test if administration of the xanthine oxidase inhibitor - Allopurinol (commonly used in the treatment of gout), given over a period of 8 weeks, will improve heart function, exercise ability and quality of life in African American Veterans with resistant hypertension.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.